This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Momenta Pharmaceuticals' Management Presents At Barclays Capital 2012 Global Healthcare Conference (Transcript)

Stocks in this article: MNTA

Momenta Pharmaceuticals, Inc. ( MNTA)

Barclays Capital 2012 Global Healthcare Conference

March 14, 2012 2:30 PM ET


Rick Shea – Chief Financial Officer


Doug Gale – Senior Analyst, Barclays Capital


Doug Gale

Good afternoon. My name is Doug Gale I cover Biotech Pharma at Barclays Capital as part of the life sciences team. I’m trying to do it in sort of integrated basis. Up next we have Momenta Pharmaceuticals represented by its CFO Rick Shea.

Clearly a company that is I think really interesting from both technology stand point as well as no shortage of news flow and excitement in the industry. Covering generics manufacturer or generics industry as a whole though I know Momenta is not a generics company, but it certainly has a lot of the elements of litigation and patent challenges that bring a lot of the intrigue and usually attracts a lot of best interest.

So perhaps at the start I think what I thought would be helpful for some people to sort of explain exactly how you define yourself as a company. And what did exactly is that you do and your platform for development of both biosimilars or you know biobetters I think you would even perhaps argue as well as potentially novel therapeutics?

Rick Shea

Okay Doug thanks very much by the way for inviting us. And what we like to say Momenta is a biotechnology company that happens to be working on developing and commercializing generic products, follow on biosimilar or bioequivalent products as well as novel products. And our aim has always been to balance the work that we are doing in the generic programs with moving forward with novel drugs as well. So I think when we first emerged back as we are going public 2004 we were thought of as a sugar company, complex sugars, heparins, polysaccharides. And we’ve also been thought of as a characterization company, a company that was good at figuring out the structure, the chemical structure of complex mixture products.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs